Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Upcoming IPO
Priced IPO
Solaredge Technologies, Inc. (SEDG)
The Marygold Companies (MGLD)
Blue Water Vaccines (BWV)
Meihua International Medical Technologies (MHUA)
Smart for Life (SMFL)
Vivakor (VIVK)
TC BioPharm Holdings (TCBP)
Direct Digital Holdings, Llc (DRCT)
Modiv (MDV)
Sky Technologies (SKYX)
Modular Medical (MODD)
HeartCore Enterprises (HTCR)
Arcellx, Inc. (ACLX)
Silver Spike Investment Corp. (SSIC)
Maris-Tech Ltd. (MTEK)
Yoshitsu Co., Ltd. (TKLF)
Tpg Inc. (TPG)
Hillstream BioPharma (HILS)
Hour Loop (HOUR)
Vigil Neuroscience, Inc. (VIGL)
More companies

Arcellx, Inc. (ACLX)

Sector - Healthcare

Price chart

N/A
Return from IPO

Company News

IPO Profile

About company

They are a clinical-stage biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. They recently announced positive preliminary results from their ongoing Phase 1 clinical trial of CART-ddBCMA, their lead ddCAR product candidate, for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM), defined as patients with either minimal response or disease progression within 60 days of last treatment. As of the November 4, 2021 data cutoff date, of the 24 patients who had been dosed, 22 were evaluable for safety analysis and 19 were evaluable for efficacy analysis, based on follow-up of at least 1 and 3 months, respectively, following treatment using the 2016 International Myeloma Working Group (IMWG) uniform response criteria for MM. These evaluable patients comprised the dose escalation cohorts for the first dose level (DL1) (n=6) and the second dose level (DL2) (n=6) and a dose expansion cohort of DL1 (safety n=10, efficacy n=7).
Industry
Cell Therapy - Immunotherapies
CEO CFO
-
Employees Founded
78 2014

Contacts

Address: 25 West Watkins Mill Road, Suite A Gaithersburg, Md 20878

Telephone: (240) 327-0603

Web page: http://www.arcellx.com

IPO information

First Trade Date 2/4/2022
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)

Shares & Volumes

Shares Initial (MM) 8.3
Shares Revised (MM) 8.3
Expected offer amount (MM) $132
Realized offer amount(MM) $124.5

Financial Data (last reporting year)

Market Cap (MM) $536.64
Revenues (MM) $0
Net Income (Loss) (MM) $-53.41

Voting

What do you think will happen with the ACLX share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
The lead left underwriter: BofA Securities

IPOs led by the firm .Pro
Profitability of conducted IPOs  ?  .Pro
1st day change  ?  .Pro
Change for the first 3 months  ?  .Pro
Underwriters
BofA Securities/ SVB Leerink/ Barclays/ William Blair
CO-Managers

Sector: Healthcare

Tweets about $ACLX

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats